OR WAIT 15 SECS
May 18, 2016.
reports that Valeant Pharmaceuticals is planning to pay CFO Robert L. Rosiello and executives Dr. Ari Kellen and Anne C. Whitaker $1 million retention bonuses, as well as “special equity awards” of $2.8 million, $3.8 million and $1.25 million, respectively, in the form of restricted stock units that vest over 18-months. Antoine Gara writes that these heavy retention bonuses "further indicate pay will be a big part of working for a kinder and gentler Valeant. Or," he adds, "perhaps, Valeant has become such a toxic workplace only heavy incentives can generate loyalty inside the company".